Clinical Trials in Chicago

Showing 10761-10780 of 20,493 trials

Study of AMV564 in Patients With AML

NCT03144245

This is a first in human, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of AMV564.

Acute Myeloid Leukemia

Amphivena Therapeutics, Inc.53 participantsStarted Mar 2017

San Francisco, California, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +7 more locations

COMPLETEDPhase 32.2 miles

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148

This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19. Eligible participants will be randomly assigned (1:1) to either treatment group (HCQ) or placebo in a double-blind fashion. Course of treatment is 30 days.

COVID-19

Adrian Hernandez1,360 participantsStarted Apr 2020

Aurora, Colorado, United States • Gainesville, Florida, United States • Jacksonville, Florida, United States +31 more locations

Study of AMV564 in Patients With AML

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

Find Trials by Condition in Chicago

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis

Dupilumab Phase 4 Study

Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease

The (PIVOTAL) Study

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

Post-market Study to Obtain Surgeon Feedback on Clinical Outcome in Eyes Implanted With TECNIS Toric II IOL

Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery

A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma